Study of investigating the mechanism of action of azacitidine in patients with myelodysplastic syndrome/acute myeloid leukemia with myelodysplasia-related changes by single cell RNA sequence

Study of investigating the mechanism of action of azacitidine in patients with myelodysplastic syndrome/acute myeloid leukemia with myelodysplasia-related changes by single cell RNA sequence - scRNA-Aza

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042515

Enrollment

Registered

2020-11-24

Start date

2020-03-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myelodysplastic syndrome,acute myeloid leukemia with myelodysplasia-related changes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with high-risk MDS and AML-MRC who underwent or who are undergoing AZA therapy

Exclusion criteria

Exclusion criteria: underage

Design outcomes

Primary

Measure	Time frame
To investigate the serial single cell transcriptome profile in responder versus non-responder	—

Countries

Japan

Contacts

Public ContactKAZUAKI YOKOYAMA

Research Hospital, The Institute of Medical Science Department of Hematology/Oncology

k-yoko@ims.u-tokyo.ac.jp03-3443-8111

Outcome results